{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:19Z","timestamp":1791476059315,"version":"4.3.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Orally administered small-molecule drugs including tyrosine kinase 2 (TYK2) inhibitors and phosphodiesterase 4 (PDE4) inhibitors are new candidates for systemic therapy in plaque psoriasis. However, no previous articles evaluated the benefit and risk profile of TYK2 and PDE4 inhibitors in psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study was to compare the efficacy and safety of oral small-molecule drugs, including TYK2 and PDE4 inhibitors, in treating moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, and Cochrane library were searched for eligible randomized clinical trials (RCTs). Response rates for a 75% reduction from baseline in Psoriasis Area and Severity Index (PASI-75) and Physician\u2019s Global Assessment score of 0 or 1 (PGA 0\/1) were used for efficacy assessment. Safety was evaluated with the incidence of adverse events (AEs). A Bayesian multiple treatment network meta-analysis (NMA) was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 13 RCTs (five for TYK2 inhibitors and eight for PDE4 inhibitors) involving 5274 patients were included. The study found that deucravacitinib at any dose (except for 3 mg QOD), ropsacitinib (200 and 400 mg QD), and apremilast (20 and 30 mg BID) had higher PASI and PGA response rates than placebo. In addition, deucravacitinib (3 mg BID, 6 mg QD, 6 mg BID, and 12 mg QD), and ropsacitinib (400 mg QD) showed superior efficacy than apremilast (30 mg BID). In terms of safety, deucravacitinib or ropsacitinib at any dose did not lead to a higher incidence of AEs than apremilast (30 mg BID). The ranking analysis of efficacy revealed that deucravacitinib 12 mg QD and deucravacitinib 3 mg BID had the highest chance of being the most effective oral treatment, followed by deucravacitinib 6 mg BID and ropsacitinib 400 mg QD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oral TYK2 inhibitors demonstrated satisfactory performance in treating psoriasis, surpassing apremilast at certain doses. More large-scale, long-term studies focusing on novel TYK2 inhibitors are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      PROSPERO (ID: CRD42022384859), available from:\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022384859<\/jats:uri>\n                      , identifier CRD42022384859.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1180170","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:09:24Z","timestamp":1685700564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuanyuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000350008","article-title":"Cumulative life course impairment: evidence for psoriasis","volume":"44","author":"Mattei","year":"2013","journal-title":"Curr Probl Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0144-3","article-title":"Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast","volume":"29","author":"Gooderham","year":"2015","journal-title":"BioDrugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-013-0023-0","article-title":"Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases","volume":"3","author":"Wittmann","year":"2013","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B7","article-title":"Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center","volume":"12","author":"Au","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"B8","article-title":"A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies","volume":"13","author":"Levin","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"B9","article-title":"Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis","volume":"14","author":"Garber","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2403","article-title":"Unmet needs in the treatment of psoriasis","volume":"24","author":"Kragballe","year":"2014","journal-title":"Eur J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21263","article-title":"Small molecules in the treatment of psoriasis","volume":"76","author":"Torres","year":"2015","journal-title":"Drug Dev Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/idoj.IDOJ_437_18","article-title":"Apremilast in psoriasis and beyond: big hopes on a small molecule","volume":"10","author":"Afra","year":"2019","journal-title":"Indian Dermatol Online J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0190","article-title":"Small-Molecule-Based immunotherapy for immunologically mediated skin conditions","volume":"12","author":"Sernicola","year":"2020","journal-title":"Immunotherapy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000001351","article-title":"Advances in small molecule inhibitors for treatment of psoriasis","volume":"134","author":"Chen","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/ptt.S303634","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"11","author":"Milakovic","year":"2021","journal-title":"Psoriasis (Auckl)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and janus Kinase\u2212Signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0218-4","article-title":"Apremilast: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1293519","article-title":"Apremilast for the management of moderate to severe plaque psoriasis","volume":"10","author":"Vangipuram","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01261-8","article-title":"Jak inhibitors for treatment of psoriasis: focus on selective Tyk2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"Tyk2\/Jak1 inhibitor pf-06700841 in patients with plaque psoriasis: phase iia, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor pf-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-Severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30397-0","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral Tyk2 inhibitor pf-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study","volume":"3","author":"Tehlirian","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2307\/1390675","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1997","journal-title":"J Comput Graphical Stat"},{"key":"B26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","article-title":"Efficacy and safety of apremilast in patients with mild-to-Moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Stein Gold","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04716.x","article-title":"Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase ii, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study","volume":"27","author":"Papp","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (Pde4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase iii, randomized, controlled trial (Efficacy and safety trial evaluating the effects of apremilast in psoriasis [Esteem] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-Severe plaque psoriasis over 52 weeks: a phase iii, randomized controlled trial (Esteem 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-Severe plaque psoriasis: 52-week results from a phase iiib, randomized, placebo-controlled trial (Liberate)","volume":"31","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13829","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial","volume":"44","author":"Ohtsuki","year":"2017","journal-title":"J Dermatol"},{"key":"B33","article-title":"Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower bsa: week 16 results from the unveil study","volume":"16","author":"Strober","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 poetyk pso-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of tyk2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B37","unstructured":"Prescribing information for otezla (Apremilast)2014"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - a network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12555","article-title":"Newer treatments of psoriasis regarding il-23 inhibitors, phosphodiesterase 4 inhibitors, and janus kinase inhibitors","volume":"30","author":"Wcis\u0142o-Dziadecka","year":"2017","journal-title":"Dermatol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"B41","article-title":"Mechanisms underlying the clinical effects of apremilast for psoriasis","volume":"17","author":"Pincelli","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of janus kinase (Jak) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9","article-title":"Jak-stat signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic jak inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00720-0","article-title":"Deucravacitinib for the treatment of psoriatic disease","volume":"23","author":"L\u00e9","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605","article-title":"Tyk 2 inhibitors for the treatment of dermatologic conditions: the evolution of jak inhibitors","volume":"61","author":"Jo","year":"2022","journal-title":"Int J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1409205","article-title":"Advances in treating psoriasis in the elderly with small molecule inhibitors","volume":"18","author":"Cline","year":"2017","journal-title":"Expert Opin Pharmacother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1180170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:09:32Z","timestamp":1685700572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1180170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2023.1180170"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1180170","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"article-number":"1180170"}}